Prescriber Criteria Form

Sporanox Capsules 2024 PA Fax 1432-A v1 010124.docx Sporanox (itraconazole capsules) Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673**.

Please contact CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process.

When conditions are met, we will authorize the coverage of Sporanox (itraconazole capsules).

Drug Name:

Patient Phone:		
State:	Zip:	
Prescriber Fax:	·	
ICD Code(s):		
	State: Prescriber Fax:	State: Zip: Prescriber Fax:

Please circle the appropriate answer for each question.				
1	Will the requested drug be used orally?	Yes	No	
	[If no, then no further questions.]			
2	Does the patient have a diagnosis of onychomycosis due to dermatophytes (Tinea unguium) which has been confirmed by a fungal diagnostic test (e.g., potassium hydroxide [KOH] preparation, fungal culture, or nail biopsy)? [If yes, then no further questions.]	Yes	No	
3	Is the requested drug being used for any of the following: A) Disseminated histoplasmosis, B) Central nervous system (CNS) histoplasmosis, C) Histoplasmosis prophylaxis in HIV infection, D) Coccidioidomycosis prophylaxis in HIV infection, E) Invasive fungal infection prophylaxis in chronic granulomatous disease, F) Primary treatment for chronic cavitary or subacute invasive (necrotizing) pulmonary aspergillosis? [If yes, then no further questions.]	Yes	No	
4	Is the requested drug being used for any of the following: A) Blastomycosis, B) Histoplasmosis, C) Aspergillosis in a patient intolerant of or refractory to amphotericin B therapy, D) Coccidioidomycosis, E) Cryptococcosis, F) Microsporidiosis, G) Talaromycosis (formerly Penicilliosis), H) Sporotrichosis, I) Pityriasis versicolor, J) Tinea versicolor, K) Tinea corporis, L) Tinea cruris, M) Tinea capitis, N) Tinea manuum, O) Tinea pedis, P) Invasive fungal infection prophylaxis in a liver transplant patient, Q)	Yes	No	

	[If yes, then no further questions.]		
5	Is the requested drug being used as primary treatment for allergic bronchopu aspergillosis? [If no, then no further questions.]	Ilmonary Yes	No
6	Will the requested drug be initiated in combination with systemic corticostero	ids? Yes	No
Comm	nents:		
, ,	ning this form, I attest that the information provided is accurate and true as of thi nentation supporting this information is available for review if requested by the he		